Press review · Friday, 23 October 2026

1. 26 October 2026: 3 articles
3. 24 October 2026: 1 articles
4. 23 October 2026: 2 articles
5. 22 October 2026: 6 articles
6. 21 October 2026: 3 articles
7. 20 October 2026: 4 articles
8. 19 October 2026: 5 articles
9. 18 October 2026: 1 articles
10. 17 October 2026: 1 articles
11. 16 October 2026: 1 articles
12. 15 October 2026: 2 articles
13. 14 October 2026: 4 articles
14. 13 October 2026: 4 articles
15. 12 October 2026: 2 articles
16. 11 October 2026: 1 articles
26. Oct 2026
56. Sep 2026
87. Aug 2026
118. Jul 2026
120. 29 June 2026: 413 articles
138. 11 June 2026: 22 articles
140. 09 June 2026: 8 articles
141. 08 June 2026: 1 articles
143. 06 June 2026: 1 articles
148. Jun 2026
157. 23 May 2026: 26 articles
173. 07 May 2026: 11 articles
179. May 2026
185. 25 April 2026: 9 articles
196. 14 April 2026: 9 articles
209. Apr 2026
240. Mar 2026
268. Feb 2026
299. Jan 2026
328. 03 December 2025: 152 articles
330. Dec 2025
337. 24 November 2025: 15 articles
360. Nov 2025
386. 06 October 2025: 67 articles
391. Oct 2025
421. Sep 2025
447. 06 August 2025: 183 articles
452. Aug 2025
455. 29 July 2025: 20 articles
457. 27 July 2025: 5 articles
460. 24 July 2025: 9 articles
461. 23 July 2025: 4 articles
481. 03 July 2025: 39 articles
483. Jul 2025
494. 20 June 2025: 34 articles
503. 11 June 2025: 25 articles
505. 09 June 2025: 10 articles
513. Jun 2025
519. 26 May 2025: 33 articles
520. 25 May 2025: 1 articles
522. 23 May 2025: 2 articles
524. 21 May 2025: 7 articles
525. 20 May 2025: 6 articles
527. 18 May 2025: 3 articles
528. 17 May 2025: 4 articles
529. 16 May 2025: 7 articles
530. 15 May 2025: 1 articles
531. 14 May 2025: 1 articles
537. May 202508 May 2025: 6 articles

1,174 articles: 08 May 2025 – 26 October 2026

1. Nnbcnews.com 3 days ago
   

   Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

   The results are seen as a boost to field of cancer vaccine research.

2. arstechnica.com 3 days ago
   

   Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

   Markers released top-line results today after previously reporting the trial succeeded.